CARA Nasdaq

Cara Therapeutics, Inc.

CARA | $0.6716 -5.02% -4.34% 220K

(0.0% 1d) (-8.2% 1m) (-83.3% 1y) (0.0% 2d) (-5.6% 3d) (1.5% 7d) (19.52% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 36,714,410
http://www.caratherapeutics.com
Sec Filling | Patents | 67 employees

(US) CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

opioid analgesic aesthetic

add to watch list Paper trade email alert is off

Press-releases

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -25.97% | O: 0.03% H: 2.62% C: 1.57%
conference therapeutics

Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
Published: 2024-03-07 (Crawled : 12:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -32.33% | O: 2.01% H: 5.94% C: 3.96%
therapeutics

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -32.99% | O: -11.58% H: 6.39% C: 2.94%
year therapeutics financial results

Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Published: 2024-02-12 (Crawled : 21:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| 14.92% | O: -0.34% H: 1.55% C: -8.23%
year therapeutics financial results

Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
Published: 2024-01-22 (Crawled : 12:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| 18.58% | O: 1.84% H: 4.31% C: -2.9%
program therapeutics

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -45.53% | O: -4.88% H: 0.0% C: -46.23%
pruritus dermatitis therapeutics study

Cara Therapeutics Reports Third Quarter 2023 Financial Results
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -43.22% | O: -0.85% H: 0.0% C: -6.41%
therapeutics financial results

Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -44.63% | O: 0.83% H: 6.56% C: -2.46%
royalty therapeutics agreement

Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -48.06% | O: 0.78% H: 0.0% C: -5.38%
therapeutics financial results

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
CARA | $0.6716 -5.02% -4.34% 220K

Health Technology

| -59.88% | O: 1.8% H: 4.12% C: 0.59%
korsuva pruritus japan hemodialysis approval treatment therapeutics injection

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-010570	4	2024-04-09	2024-04-05	Sell	S	2753	53365
0001415889-24-006282	4	2024-03-04	2024-02-29	Sell	S	3293	91000
0001415889-24-002515	4	2024-02-05	2024-02-01	Buy	A	13500	167247
0001415889-24-002513	4	2024-02-05	2024-02-01	Sell	S	4981	221930
0001415889-24-002513	4	2024-02-05	2024-02-01	Buy	A	62500	226911